Menu
Back to Journals » OncoTargets and Therapy » Volume 9
Review
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 10,049 | Dovepress* | 9,101+ | 1,348 | 10,449 | |
| PubMed Central* | 948 | 323 | 1,271 | ||
| Totals | 10,049 | 1,671 | 11,720 | ||
|
*Since 10 May 2016 +Since July 2016 |
|||||
View citations on PubMed Central and Google Scholar